Glutamine-utilizing enzymes (broad glutamine metabolism pathway)

Class

Glutamine antagonist prodrug (pan-glutaminase pathway inhibitor)

Pathway

Inactive prodrug of the broad-acting glutamine antagonist DON (6-diazo-5-oxo-L-norleucine); preferentially activated within tumors, where it covalently and irreversibly inhibits approximately 10 glutamine-metabolizing enzymes, disrupting tumor glutamine metabolism and stimulating innate/adaptive immunity

Glutamine is an amino acid that many tumor cells consume at high rates to fuel energy production, biosynthesis of nucleotides and other building blocks, and antioxidant defense—a dependency often called glutamine addiction. This dependency creates a therapeutic rationale for blocking glutamine metabolism broadly rather than targeting a single enzyme in the pathway, since tumors can often reroute around the loss of any one node. DON (6-diazo-5-oxo-L-norleucine) is a molecule that irreversibly and covalently inactivates roughly ten different glutamine-utilizing enzymes, shutting down multiple metabolic routes simultaneously. Historically, DON's usefulness was limited by toxicity to normal, rapidly dividing tissues that also rely on glutamine, such as the gut lining and bone marrow. The prodrug approach described here is designed to remain largely inactive in circulation and to be converted to active DON preferentially within tumor tissue, aiming to concentrate the effect where it is wanted while sparing healthy tissue. Beyond direct tumor effects, restricting glutamine availability in the tumor microenvironment can also influence immune cells, potentially shifting the metabolic competition in favor of immune cells that attack the tumor. This class of mechanism is relevant across cancers characterized by heavy reliance on glutamine-fueled metabolism.